联系我们

论文查询结果	返回搜索

论文编号：	6104
作者编号：	2220130021
上传时间：	2014/5/27 9:09:29
中文题目：	北京五和博澳公司跨行业转型及相关多元化研究
英文题目：	Study on cross-industry transitionand relateddiversification of Beijing Wehand-bio Company
指导老师：	张玉利
中文关键字：	跨行业转型;相关多元化;医药产业;战略
英文关键字：	Cross-industryTransition;Related Diversification;Pharmaceutical Industry;Strategy
中文摘要：	生物医药是国家重点发展的高新技术产业，易形成技术壁垒，回报率高且抵御金融危机的能力较强，一直是房地产等业外投资机构高度关注和青睐的焦点，但因专业性强、投资大、周期长、风险高，准入门槛特殊，投资者们大多停留在股权等资本运作层面而较少深入到实体经济的创建。 一方面，我国的房地产行业产能过剩，需要向高新技术的实体经济转型，而另一方面，医药产业结构升级刻不容缓，需要更多的社会资金介入与支持。但由于没有成熟可借鉴的投资模式与经验，缺乏管理学与经济学工具与模型，限制了技术与资本的对接，严重影响到我国的投资环境和生物医药产业的健康发展，这已引起经济学界、投资界和医药产业界学者高度关注。 企业跨行业转型尤其是向生物医药高新技术产业方向转型，低谷期是最佳的介入时机；企业不仅要有长期投资的资金实力，还要遵循大投资高起点的发展理念；新药项目遴选要注重自主知识产权、临床市场导向和国际化临床评价，由此提高企业的核心竞争力；以高端药品为核心，延伸到健康关联产业，打造相关多元化发展战略，可最大限度发挥资源配置优势，提高企业综合实力。通过资源整合加强创新团队建设，构建协同创新的企业文化，强化企业对行业发展的引领作用，是企业获得可持续发展的重要保障。 本文以北京五和博澳药业发展为例，从经济学和产业发展的视角，对企业转型和定位战略进行研究，探讨产业方向和介入时机选择及投资理念对转型战略的影响，从新药项目定位及相关多元化结构布局等层面，探讨了医药为核心的相关多元化战略要素及其逻辑关系，最后对企业未来可持续发展过程中的关键因素进行分析并提出了相应对策。 通过本论文研究，对五和博澳跨行业转型与相关多元化战略进行了梳理，阐述了企业战略的逻辑思维，研究结果丰富了管理学内容，有利于推动五和博澳的可持续发展与创新，对业外资金投入医药产业实体经济具有指导意义及借鉴价值。
英文摘要：	Pharmaceuticalindustryis one of national highly developed high-tech industries, which isof technical barriers, high return rate and a strong ability to withstand the financial crisis. So,pharmaceutical industryhas been the focus of real estate and other investment institutions, but the feather of professionality, biginvestment, long cycle, high-risk, special barriers prevent mostinvestors to enter the filed。 On the one hand, China's real estate industry isof overcapacity, and needs to transitto high-tech industry. On the other hand, the pharmaceutical industry is facing structure upgrade, and in the urgent need of more involvement andsocial capital investment. The lack of a mature investment model limited the combinationof the technology and capital, seriously affected the healthy development of China's investment environment and pharmaceutical industry, which has attractedthe attention of theeconomists, the investment community and the pharmaceutical industry researchers. The right time to intervene is the key factor of transition, especially cross-industry transition to high-tech pharmaceutical industry, as well as the concept of large investment as starting point, the financial strength of long-term investment, drug selection,market-oriented projects with core competitiveness, innovation, technical barriers and international clinical trial. It is of the most importance forimproving the comprehensive competitiveness to extend the health related industries chain with high-end drugs as its core, to develop related diversification strategy, and to share technology and resources. For the sustainable development of enterprises,it is an important guarantee to strengthen the innovative team building through integration of resources, to build collaborative and innovative corporate culture, and tomaintain the leading role of business development in the industry. The thesis, taking the wehand-bio company for example,from the perspective of economic and industrial development, investigatethe enterprise transition and position strategiesfrom the impact of industry direction, the interventiontimeand investment philosophy, and study on medicine-related diversification strategy from drug project location, the layout of related diversification industry chain and creative team building. This thesis is to enrich the content of managementand management tools, to provide a reference for the industry outside capital intothe pharmaceutical industry, and to promote structure upgrading and development of pharmaceutical industry in China.
查看全文：	预览  下载(下载需要进行登录)